Prostate-specific membrane antigen (PSMA)-PET/CT is a valid alternative to MRI as a staging tool because it is considered the most sensitive technique for detecting low volume metastatic prostate cancer.1 The gene discussed is FOLH1; the disease is metastatic prostate carcinoma.